In most developing countries, rubella vaccine has not been included in the Expanded Programme on Immunization because of lack of information on the burden of disease caused by rubella virus, increased cost associated with adding rubella vaccine, and the concern that if high vaccine coverage cannot be achieved and maintained, the risk of congenital rubella syndrome (CRS) may increase. Data for 2009 reported by countries to the World Health Organization (WHO) and United Nations Children's Fund through the annual Joint Reporting Form were used to indicate patterns in the worldwide use of rubella vaccines, describe the number of reported rubella and CRS cases by WHO Region, and explore factors associated with decisions by countries to introduce rubella vaccine in their national childhood immunization programs. The number of WHO Member States using rubella-containing vaccine (RCV) in their national childhood immunization schedule increased from 83 (43%) in 1996 to 130 (67%) in 2009. Although scheduled ages for rubella vaccination vary across countries and regions, most countries have a 2-dose schedule using a combined measles-mumps-rubella vaccine. Among 130 countries using RCV in 2009, median coverage with the first dose of measles-containing vaccine (MCV1) was 95% (interquartile range [IQR], 90%-98%), compared with a median MCV1 coverage of 76% (IQR, 64%-88%) in countries not using RCV.
In most developing countries, rubella vaccine has not been included in the Expanded Programme on Immunization because of lack of information on the burden of disease caused by rubella virus, increased cost associated with adding rubella vaccine, and the concern that if high vaccine coverage cannot be achieved and maintained, the risk of congenital rubella syndrome (CRS) may increase. Data for 2009 reported by countries to the World Health Organization (WHO) and United Nations Children's Fund through the annual Joint Reporting Form were used to indicate patterns in the worldwide use of rubella vaccines, describe the number of reported rubella and CRS cases by WHO Region, and explore factors associated with decisions by countries to introduce rubella vaccine in their national childhood immunization programs. The number of WHO Member States using rubella-containing vaccine (RCV) in their national childhood immunization schedule increased from 83 (43%) in 1996 to 130 (67%) in 2009. Although scheduled ages for rubella vaccination vary across countries and regions, most countries have a 2-dose schedule using a combined measles-mumps-rubella vaccine. Among 130 countries using RCV in 2009, median coverage with the first dose of measles-containing vaccine (MCV1) was 95% (interquartile range [IQR] , 90%-98%), compared with a median MCV1 coverage of 76% (IQR, 64%-88%) in countries not using RCV. The median per capita gross national income among 130 countries using RCV was US $6300 (IQR, $3227-$20 916), compared with $635 (IQR, $337-$1027) for 63 countries not using RCV. In 2009, 121 344 rubella cases from 167 countries were reported to WHO. However, only 165 CRS cases were reported globally, of which 67 were in the Eastern Mediterranean Region. Further improvements in surveillance are needed to better document the burden of CRS, and new financing mechanisms will be required to catalyze the introduction of rubella vaccine in developing countries that currently meet the coverage criteria for introduction of rubella vaccine.
Rubella vaccines were first licensed in the United States in 1969, and during the 1970s and 1980s, their use became widespread in industrialized countries [1] . In 1996, the burden of congenital rubella syndrome (CRS) in developing countries was estimated to be 110 000 cases (range, 14 000-308 000 cases), with the Southeast Asian, African, American, Western Pacific, and East Mediterranean Regions of the World Health Organization (WHO) accounting for 43%, 20%, 15%, 12%, and 11% of cases, respectively [2] . However, in most developing countries, rubella vaccine has not been included in the Expanded Programme on Immunization (EPI) because of lack of information on the burden of disease caused by rubella virus, increased cost associated with adding the rubella vaccine component, and the concern that if high vaccine coverage cannot be achieved and maintained, the risk of CRS may increase because of a shift in rubella virus susceptibility to older age groups, including women of child-bearing age [3] .
As of October 2010, Member States of 2 of the 6 WHO Regions had established goals to eliminate rubella and CRS-the Americas by 2010 and the European Region by 2015. (During the September 2010 WHO Regional Committee for Europe meeting, the year for reaching the goal of eliminating measles and rubella and prevention of CRS was changed to 2015.) The Region of the Americas is on track to achieve rubella and CRS elimination [4] . Another WHO region (Western Pacific) has established a goal of accelerated rubella control and CRS prevention by 2015. The other 3 regions (Eastern Mediterranean, Southeast Asian, and African) do not have rubella or CRS control or elimination goals. However, a number of countries in these regions have introduced rubella vaccines and have national control goals. This article updates a previous report on the worldwide use of rubella vaccines and explores factors associated with decisions by countries to introduce rubella vaccine in their national childhood immunization programs [3] .
METHODS
Data reported from WHO Member States on the WHO-United Nations Children's Fund Joint Reporting Form on Immunization (JRF) from 1980 through 2009 were used to ascertain whether rubella-containing vaccine (RCV) was included in the national childhood immunization schedule, the number and timing of recommended doses, and the number of reported cases of rubella and CRS.
For countries where use of a combined measles-mumpsrubella (MMR) vaccine or measles-rubella (MR) vaccine was reported, annual estimates of rubella vaccination coverage for the period 1980-2009 were based on the WHO-UNICEF estimates of coverage with the first dose of measles-containing vaccine (MCV1) [5] .
Because the WHO recommends that RCV only be introduced in countries where MCV1 coverage is .80% [6] , MCV1 coverage was analyzed among countries that either use or do not use RCV in their routine program [7] . Because previous reports have noted that RCV was predominantly used in industrialized countries, we analyzed RCV use by gross national income (GNI) taken from the 2006 World Economic Report compiled by the World Bank [8] . Box plots were used to compare the distributions of MCV1 coverage and GNI among countries using or not using RCV in their national immunization schedule. In box plots, the median value is indicated by a line in the center of the box; the upper and lower edges of the box reflect the interquartile range ( 
RESULTS
During the 1980s, there was a gradual increase in the number of countries recommending RCV in their national immunization schedule ( Figure 1 ). With use of the global birth cohort as a denominator, global coverage with RCV remained ,10% during this period. The number increased from 83 (43%) in 1996 to 130 (67%) in 2009 (Table 1) . Among the 47 new countries recommending RCV, 14 were in the American Region, 14 in the European Region, 11 in the Western Pacific Region, 6 in the Eastern Mediterranean Region, and 2 in Southeast Asian Region. During the corresponding period, global RCV coverage increased from 12% to 27%. In 2009, regional RCV coverage was highest in the European (94%) and American (93%) Regions, 40% in Eastern Mediterranean, 17% in Western Pacific, and ,5 % in both Southeast Asian and African Regions.
As of 2009, all countries in the American Region and European Region had introduced rubella vaccination (Figure 2 ). In the Eastern Mediterranean Region, all Persian Gulf countries and countries in North Africa use RCV. In the Western Pacific Region, RCV is routinely recommended in Australia, New Zealand, Japan, Brunei Darussalam, Republic of Korea, Malaysia, Singapore, Mongolia, Philippines, China, and 11 of the 13 Pacific Island countries. In the Southeast Asian Region, Thailand, Bhutan, Maldives, and Sri Lanka use RCV, and in the African Region, RCV use is limited to 2 island countries (the Seychelles and Mauritius).
In 2009, 122 (94%) of the 130 countries with RCV in the national childhood immunization schedule recommended administering the first dose of RCV during the second year of life, including 78 countries recommending at 12 months of age and 44 countries at ages 1 and 2 years. Four countries (Bhutan, China, Haiti, and Mongolia) recommend rubella vaccination before 12 months of age, and 4 countries recommend it after 2 years of age (Thailand at entry to first grade, Sri Lanka at age 3 years, Tunisia at age 12 years for girls only, and Morocco at age 6 years).
Only 1 dose of RCV is required for long-term protection. However, most countries use a 2-dose schedule because rubella vaccine is generally combined with measles vaccine, which is recommended as a 2-dose schedule. In 2009, 119 countries (92%) recommended 2 doses of RCV, and 11 (8%) countries recommended a single dose of RCV. Of the countries that recommended a single dose of RCV for young children, 6 recommended a catch-up dose for adolescents.
MMR vaccine is used in 117 countries (90%; including China and the Russian Federation [China uses MR and MMR vaccines, and Russia uses rubella MR and MMR vaccines]); MR is used in 12 countries (9%; Bhutan, Fiji, Haiti, Japan [Japan uses rubella vaccine and MR vaccine], Kiribati, Morocco, Nauru, Samoa, Sri Lanka, Tajikistan, Tonga, and Tuvalu); combined measlesmumps-rubella-varicella vaccine is used in 2 countries (2%; Germany and Israel); and single antigen rubella vaccine is used in 1 country (Tunisia).
Among 130 countries using RCV in 2009, the median MCV1 coverage was 96% (IQR, 92%-99%), including 9 countries (Azerbaijan, Cook Islands, Dominican Republic, Ecuador, Haiti, Iraq, Lebanon, Palau, and Samoa) with MCV1 coverage ,80%. For countries not using RCV, the median MCV1 coverage was 76% (IQR, 74%-91%) (Figure 3) .
The median per capita GNI among 130 countries using RCV was US $6300 (IQR, $3227-$20 916), compared with US $635 (IQR, $337-$1027) for 66 countries not using RCV (Figure 4 Among the 20 countries with MCV1 coverage .80% for 3 consecutive years and not using RCV in their national immunization programs, all are using or plan to introduce hepatitis B vaccine, 17 are using or plan to introduce Haemophilus influenzae type b vaccine, 2 are using and 4 have been approved for introduction of conjugate pneumococcal vaccine, and 1 has been approved for rotavirus vaccine (Table 2) . Financial support for introduction of these newer vaccines (excluding rubella vaccine) is available to 16 of these 20 countries through GAVI.
Diagnosis and reporting of patients with rubella or congenital rubella syndrome is weak in many countries. In 2009, 121 344 rubella cases from 168 countries were reported to the WHO through the JRF (Table 3 ). All countries in the American Region (except the United States) reported rubella cases, as did 46 of 53 countries in the European Region and 38 of 46 African countries. The proportion of countries reporting rubella cases was substantially lower in the other 3 WHO regions. Only 165 CRS cases were reported globally, of which 67 were in the Eastern Mediterranean Region.
DISCUSSION
Over the past decade, there has been a steady increase in the number of countries using RCV, such that rubella vaccine is now part of the national immunization schedule in approximately two-thirds of the countries and territories of the world. Rubellacontaining vaccines are highly protective and without significant adverse effects, and when compared with the long-term costs of caring for patients with CRS, rubella vaccination has been shown to be cost effective in both industrialized and developing countries [9] . However, more than half of the global birth cohort live in countries that do not include rubella vaccination in their national immunization program, and pregnant women in these countries rely on immunity acquired through natural rubella infection. Although most of these infections occur during childhood, some may occur during the first trimester of pregnancy, resulting in congenital rubella infection of the fetus and its damaging consequences.
One of the main reasons for not introducing rubella vaccine has been concern about the ability to achieve and sustain immunization coverage .80%. If a childhood vaccination program is inadequately implemented, there is a potential risk of altering the rubella transmission dynamics, which can lead to an increase in susceptibility in women of childbearing age, with the potential of increased numbers of cases of CRS. During 2000-2009, global MCV1 coverage increased from 71% to 82%, making more countries eligible for use of RCV. As of 2009, there were 133 countries with MCV1 coverage .80% for at least 3 consecutive years, of which 20 had not introduced RCV into their national immunization schedule. All 20 countries have conducted measles catch-up campaigns that have reduced measles incidence to low levels, and all have introduced casebased surveillance for measles. Laboratory testing of suspected measles cases that are measles IgM negative continues to show that a high proportion are rubella IgM positive and are presumptive rubella cases [10] . In China, a progressive increase in the median age of patients with rubella, indicating an increasing risk of CRS cases, has led to inclusion of rubella vaccine into the national immunization schedule starting in 2008 (Ministry of Health, China. Implementation Plan of the Expanded National Immunization Program).
Despite the availability of combined MR and MMR vaccines at affordable prices (In 2010 the UNICEF discounted price per dose was US $0.93-$1.60 for MMR and US $0.53 for MR compared with US $0.22 for M; http://www.unicef.org/supply/ files/2010_Vaccine_Projection.pdf.) and proven cost effectiveness of rubella vaccination [9] , political commitment for introduction of rubella vaccine in many developing countries and among major donors has been less than optimal. Several factors historically have played a role in creating this situation. First, the burden of CRS is often missed because it is difficult to diagnose in settings with limited medical facilities and it affects as few as 1 in 10 000 pregnancies during the period between rubella epidemics. However, the implementation of surveillance for febrile 
rubella) has greatly increased the awareness of the ubiquity of rubella worldwide wherever rubella vaccine is not in widespread use [10] . Second, the focus of the Millennium Development Goals on reducing childhood mortality may have the unintended consequence of minimizing the importance of diseases, such as rubella, that are readily preventable but associated primarily with disability rather than deaths in children. Third, marketing of newer vaccines against rotavirus infection, invasive pneumococcal disease, and human papilloma virus may overshadow rubella vaccine because of their greater impact on reducing deaths and much higher commercial profitability relative to a mature market vaccine, such as rubella vaccine, that has been available for 40 years. Rubella vaccine is being considered by the GAVI Alliance and other donor organizations as one of a group of vaccines targeted for strategic support [11] . The remarkable progress made toward rubella elimination in the Americas should provide impetus for further investments globally and offer the prospect of increased rubella vaccine uptake, particularly in the GAVI-eligible countries meeting WHO criteria for vaccine introduction.
The decision to introduce new vaccines is made at the country level and requires careful consideration of factors such as the disease burden, public health importance relative to other diseases, cost effectiveness, and affordability of the intervention [12] . In addition, establishment of regional elimination goals can play a major role in the development of the political commitment and sustained financing in countries with weaker immunization systems. This is particularly evident in the Region of the Americas, where countries with weak immunization systems (eg, Haiti) have received political, financial, and programmatic support for rubella vaccination as part of the region-wide effort to eliminate rubella and CRS.
With the availability of new vaccines, much emphasis is being placed on the capacity of developing countries to make the complex decisions relating to vaccine introduction [12, 13] . The public health benefits of rubella vaccine should not be overlooked in this process. Improved surveillance for rubella and CRS remains the most effective way to keep rubella vaccine on the list of vaccines for introduction. Recent progress in measles control and improved surveillance for febrile rash illnesses has unmasked the underlying occurrence of rubella. However, CRS cases are grossly under-reported to WHO in all regions outside the Americas. Further improvements in surveillance are needed to better document the burden of CRS. Although rubella surveillance is easily combined with an already improving measles surveillance, CRS surveillance is more labor intensive, involving different groups of clinicians and institutions. New financing mechanisms are needed to catalyze the introduction of rubella vaccine in countries that currently meet the coverage criteria for introduction of rubella vaccine. The rapid progress toward rubella and CRS elimination in the Americas provides a powerful example for other countries and regions striving to prevent human suffering, consequences in terms of disability and death, and costs associated with rubella infection during pregnancy.
